Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis

doi:10.4330/wjc.v14.i11.599

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 11

This Article

(211)

(158)

(0)

(8)

(1)

(4937)

(9)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Meta-Analysis

World J Cardiol. Nov 26, 2022; 14(11): 599-616
Published online Nov 26, 2022. doi: 10.4330/wjc.v14.i11.599

Full Size Figure Download Figure

Figure 6 Forest plot highlighting the absence of significant impact of SGLT2-I on HDL compared to placebo. SGLT2-I: Sodium-glucose cotransporter 2 inhibitor; HDL: High-density lipoprotein.

Citation: Olagunju A, Yamani N, Kenny D, Mookadam M, Mookadam F, Unzek S. Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis. World J Cardiol 2022; 14(11): 599-616
URL: https://www.wjgnet.com/1949-8462/full/v14/i11/599.htm
DOI: https://dx.doi.org/10.4330/wjc.v14.i11.599

Olagunju A, Yamani N, Kenny D, Mookadam M, Mookadam F, Unzek S. Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis. World J Cardiol 2022; 14(11): 599-616 [PMID: 36483765 DOI: 10.4330/wjc.v14.i11.599]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.